Tag

BMWS

Biopharmaceutical Industry Trends and the Power of Data — A Conversation with Dan Szot and Chris Andrews of BIOVIA, Dassault Systèmes Company
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Biopharmaceutical Industry Trends and the Power of Data — A Conversation with Dan Szot and Chris Andrews of BIOVIA, Dassault Systèmes Company

December 17, 2021

At the 2021 edition of the Biomanufacturing World Summit series held November 15-16 in San Diego, CA, Dan Szot and Chris Andrews of BIOVIA, Dassault Systèmes Company spoke about where the biopharmaceutical industry is today, how it has weathered the global pandemic, and the crucial role data has played in allowing organizations to understand where they are, what they need, and how things can move forward towards successful outcomes through informed decision-making. — Dassault Systèmes Company BIOVIA solutions create an unmatched scientific management environment that can help science-based organizations create and connect biological, chemical and material innovations to improve the…

Continue reading
How to Make the Bio-Revolution a Reality: Building Bayer’s Cell & Gene Therapy Platform
LIFE SCIENCES, VIDEO, LIFE SCIENCES

How to Make the Bio-Revolution a Reality: Building Bayer’s Cell & Gene Therapy Platform

November 30, 2021

How Bayer AG built its Cell & Gene Therapy unit New business model joining best of Biotech and best of Pharma How to build a sustainable pipeline? How to manage complexity and keep focus? What are the “must haves”? what are the learnings on common threats of significant transformations? New ways of working accelerated by COVID-19 pandemic Wolfram Carius EVP, Cell and Gene Therapy Bayer AG Prof. Wolfram Carius is the EVP, Cell and Gene Therapy at Bayer AG and is a member of the Executive Committee for Bayer Pharmaceuticals. He is based in Berlin, Germany. Prior to joining Bayer,…

Continue reading
Fighting COVID-19 with Innovation – What We Have Achieved, What We Have Learned, and What Comes Next
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Fighting COVID-19 with Innovation – What We Have Achieved, What We Have Learned, and What Comes Next

November 30, 2021

Offering an overview of how our industry responded to the global pandemic Highlighting how our organization adapted our existing processes and programs to continue to work under extraordinary circumstances Discussing some of the key takeaways and lessons learned from the past year and a half Where do we go from here? How will AstraZeneca and the biopharmaceutical industry at large move forward from here? What are we doing today to pave the way to those objectives? Pam Cheng EVP, President Global Operations & IT AstraZeneca Pam Cheng joined AstraZeneca in 2015 as executive vice president of Global Operations and Information…

Continue reading
The World of Tomorrow: Serving Patients Through Transformational Change
LIFE SCIENCES, VIDEO, LIFE SCIENCES

The World of Tomorrow: Serving Patients Through Transformational Change

November 30, 2021

How learnings from the global pandemic combined with the introduction of new technology will enable the patient-centric manufacturing of the future Highlighting what the industry should do differently to achieve an ambitious future where all patients can receive lifesaving medicines safely, swiftly, reliably and affordably Exploring how and where products will be made, and how those products will be delivered by adopting system-driven planning and automation capabilities, leveraging the power of data and advanced analytics Describing a patient-centric pipeline the industry needs in order to deliver transformative therapies for all humanity A glimpse of how the world will evolve as…

Continue reading
The Transformational Potential of the Advanced Manufacturing of Biologics
LIFE SCIENCES, VIDEO, LIFE SCIENCES

The Transformational Potential of the Advanced Manufacturing of Biologics

November 30, 2021

Describe the potential for advanced manufacturing Review case studies illustrating the potential of advantages advanced manufacturing Provide resources for product developers Peter Marks Director – Center for Biologics Evaluation and Research (CBER) Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director…

Continue reading
Panel: Looking Backwards, Looking Forwards —How Did the Last Two Years Change Us?
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel: Looking Backwards, Looking Forwards —How Did the Last Two Years Change Us?

November 30, 2021

How has working through a global pandemic impacted the way we do business? Taking stock of how we changed and why we changed. What are some of the net positives? What are some of the things where we do want to return to how things used to be? Reviewing where our organizations were five years ago and where we planned to be today, how much has COVID-19 changed the trajectory of our journeys? What are some of the lessons learned that we plan to take with us into the future? Is the community of biopharmaceutical manufacturers stronger for this experience?…

Continue reading
A Changing Biopharmaceutical Landscape: How Operations Must Be Front and Center to Enable Business Success
LIFE SCIENCES, VIDEO, LIFE SCIENCES

A Changing Biopharmaceutical Landscape: How Operations Must Be Front and Center to Enable Business Success

November 29, 2021

Discussing the changing landscape for our industry, from pricing to innovation How Operations leaders must prepare their organizations to succeed in this environment Offering a framework for balancing the need to execute in the short-term with the imperative to invest in innovation for the future Esteban Santos EVP, Operations Esteban Santos serves as executive vice president, Operations. Esteban is responsible for the Operations organization, which encompasses Manufacturing, Process Development, Quality, Engineering and Global Supply Chain. Prior to this role, Santos was senior vice president, Manufacturing, responsible for operations at Amgen’s commercial manufacturing locations in the U.S., Puerto Rico, Ireland, the…

Continue reading
Quality 4.0: Where Do I Start?
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Quality 4.0: Where Do I Start?

November 29, 2021

 Discussing the current Quality 4.0 environment and addressing the most common challenge of how to get started Applying what we’ve learned to help companies begin their quality and compliance digital initiatives by leveraging behavioral and predictive analytics Ensuring quick results and getting the most value out of your investments in Quality 4.0 initiatives Jaime Velez Co-founder Operations & Quality Systems Improvement Experts (OQSIE) For the last 15 years Jaime has supported more than one hundred consulting engagements with Life Science companies delivering significant productivity improvements in supply chain and quality systems. He started his consulting career at McKinsey &…

Continue reading
Disrupting Quality Standards (or Beliefs) Through Digitalization
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Disrupting Quality Standards (or Beliefs) Through Digitalization

January 11, 2021

 The current state of digital transformation in life science How to disrupt the quality standards: Digital transformation roadmap and the situation ongoing at SBL Digital transformation’s Value proposition: Improve quality, productivity, and for unparalleled client experience Samsung Biologics’ P4 plan and vision: We’re building the future Sam MacHour SVP & Chief Quality Officer Samsung Biologics Prior to joining Samsung Biologics in 2019, Sam spent more than 32 years supporting large MedTech, Bioscience and Biopharmaceutical companies achieve business operational excellence and gain leadership in the areas of Research & Development, Quality, Compliance, Regulatory, Operations and product commercialization. Sam’s experience covers…

Continue reading
Panel: The Past, Present and Future of the Global Bio-Pharma Supply Chain
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel: The Past, Present and Future of the Global Bio-Pharma Supply Chain

December 1, 2020

How our “new normal” is affecting our critical materials procurement and how do we adapt for the future? Examining how the proposed nationalization of our supply chains will affect risk management and operations planning What does post-COVID19 Supply Chain robustness look like? How do novel modalities (mRNA, Cell & Gene Therapy) with already existing supply chain challenges cope with these new global constraints? How will high volume ultra cold chain products affect existing specialized ultra cold chain logistics? Seismic shifts and emerging fault lines create lasting affects, what are they and how do they shape our industry in the years…

Continue reading
Accelerating Delivery of New Medicines
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Accelerating Delivery of New Medicines

December 1, 2020

Examine approaches to accelerate the pace of biopharmaceutical development across multiple platforms and modalities Clinical development velocity can affect CMC approaches, and what we’ve learned through this experience How does acceleration impact our quality, regulatory, and development functions? Understanding acceleration effects on process monitoring and analytics throughout the product lifecycle Discuss what steps we, as an industry, will need to take together to make this the new normal — John Pinion EVP Translational Sciences, Chief Quality Operations Officer Ultragenyx Pharmaceutical John Pinion has over 26 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across…

Continue reading
Panel: Looking at the Big Picture: Where is Our Industry Going, and How Should We Get There?
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel: Looking at the Big Picture: Where is Our Industry Going, and How Should We Get There?

December 1, 2020

Debating the merits of nimble and flexible facilities versus manufacturing battleships Preparing your pilot plants and manufacturing facilities to move forward with Phase II-III approvals Forecasting requirements for optimizing manufacturing equipment, facilities and partners to increase speed to market Achieving business goals to better manage times of product and economic uncertainty Putting theory into practice: Implementing key metrics to improve manufacturing flexibility — Moderators: Pat Yang Chairman at Acepodia & Founding Board Director at Sana Biotechnology Dr. Patrick Y. Yang has over 35 years leadership experience in technology, manufacturing, supply chain, and operational management functions in General Electric, Merck, Genentech,…

Continue reading
Fighting COVID-19 with Innovation – A Race Against Time
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Fighting COVID-19 with Innovation – A Race Against Time

December 1, 2020

Pam Cheng EVP, President Global Operations & IT AstraZeneca Pam Cheng joined AstraZeneca in 2015 as executive vice president of Global Operations and Information Technology (IT), guiding the company’s manufacturing, supply chain, procurement, and IT across 18 countries and leading a team of over 19,000. Under her leadership, AstraZeneca Global Operations has transformed significantly driving top performance across the business while delivering value back to the enterprise. The next phase of transformation includes the convergence of operational excellence and digital innovation, building the ‘Factory of the Future’. Before AstraZeneca she spent 18 years in global manufacturing, supply chain, and commercial…

Continue reading
COVID-19 MAbs at Pandemic Speed, Volumes and COGs
LIFE SCIENCES, VIDEO, LIFE SCIENCES

COVID-19 MAbs at Pandemic Speed, Volumes and COGs

December 1, 2020

Vir Biotech has discovered a neutralizing COVID-19 mAb to a unique, highly conserved Coronavirus spike sequence, high barrier to resistance and effector function We have partnered with numerous CDMOs and GSK to move from discovery to the clinic in approximately 6 months World-wide pandemic requirements for an efficacious neutralizing mAb may exceed 20 metric tons – challenging the capacity of industry manufacturing infrastructure — Michael Kamarck Chief Technology Officer Vir Biotechnology Michael Kamarck is Chief Technology Officer at Vir. Previously, he was senior vice president of Global Vaccines and Biologics Manufacturing and president of Merck BioVentures where he was responsible…

Continue reading

  • NASCES

  • NAFS

  • NAFMS

  • EUSCES

  • BMWS

  • NALES

  • MDMES

  • NAFES

  • NASRS

  • NAHRES

  • NAMES

  • PMWS

  • NAISS